Serge Messerlian is President, Actelion Pharmaceuticals US where he leads Actelion’s US business. He has a track record of success in complex, highly competitive markets, and experience that encompasses orphan and rare diseases, immunology, hematology and oncology. Most recently he led payer and channel growth strategies for Janssen Pharmaceuticals’ Immunology portfolio.
Serge joined Janssen in 2016 from Baxalta (formerly Baxter), where served as Vice President, Global Commercial Head, Biosimilars. Prior to that held positions of increasing responsibility within Baxter International, including Vice President, Global Marketing where he was responsible for the Rare Disease Hematology Franchise. He began his career in Canada as an award-winning sales representative for rare disease products.
Serge holds a BS in Physiology and Biotechnology and a Master of Science in Human Genetics, both from McGill University, and an MBA from the University of Toronto, Canada.
Kaylynn Callister is Head of Human Resources, Actelion Pharmaceuticals US. She has nearly 15 years of Human Resources experience across multiple sectors. In her most recent role, Kaylynn supported the Janssen North America’s Strategic Customer Group, Commercial Excellence and Business Development. She joined Johnson & Johnson in 2010 as part of the acquisition of California-based company Acclarent by Ethicon in the company’s Medical Devices sector, and she led the Acclarent HR integration into J&J. While in that role, Kaylynn was responsible for doubling the number of Acclarent employees, contributing to double-digit financial growth for the business.
Kaylynn holds a Masters in Human Resources Management from Golden Gate University and a Bachelor’s degree in Behavioral Science from Utah Valley
Assaf Guterman is Strategy and Business Planning Director. In this role, he leads Actelion’s strategy and business planning efforts, spearheads the annual planning process and serves as Chief of Staff for the Actelion Leadership Team (ALT). Assaf most recently served as Associate Director, End of Life Cycle Products, a role in which he managed Actelion’s distribution efforts, developed and implemented the company’s end-of-lifecycle products for a generic environment and drove the strategy, launch and brand management for the TRACLEER® (bosentan) 32 mg pediatric indication.
Prior to joining Actelion, Assaf held financial and business development positions of increasing responsibility within healthcare and financial institutions. Assaf earned a BA in Political Science from Tel Aviv University and an MBA in Finance from Zicklin Business School.
Bryan Huff is Head of Finance, Actelion US. He heads the Finance team responsible for all finance, accounting, financial planning and analysis activities, as well as the Corporate Services team in South San Francisco, California.
Prior to his role at Actelion, Bryan had roles of increasing responsibility within the Janssen Pharmaceuticals and Johnson & Johnson (J&J) businesses. Most recently, he served as Senior Finance Director for Business Development Finance within the J&J medical devices business, where led valuations for assessing external innovation opportunities and supported a number of acquisitions.
Bryan has lived and worked internationally while holding international roles and held marketing and operations finance roles within J&J’s US pharmaceuticals companies. Bryan holds a BS in Chemistry from Indiana University of Pennsylvania and an MBA from LaSalle University.
Bill Kaminski is Senior Director of Business Solutions Planning, Actelion Pharmaceuticals US. In this role he leads a team responsible for planning and executing the company’s strategic and operational programs. He built Actelion’s Program Management Office (PMO), which involved shifting the culture to a proactive approach and establishing standards and frameworks. He also serves as the regional PMO lead responsible for overseeing the Actelion/Janssen integration in the US.
Bill joined Actelion in 2009 from Deloitte Consulting, where he served as Senior Manager, Strategy and Operations, and led engagements focused on process improvement, shared services and M&A transactions. Bill earned a Bachelor of Science degree in Business Administration from Drexel University.
Volker Mehlo is Senior Director, Informatics. In this role he leads all sectors of Information Services, including the IT infrastructure, the IT Service Desk, business application services and information management/patient analytics for Actelion US, as well as the Canadian and Latin American affiliates.
Prior to joining Actelion in 2011, Volker held positions of increasing responsibility at Roche. Most recently he served as Head of Informatics at Roche’s Palo Alto campus. In that role, he led a team that managed all commercial and administration information systems and applications, as well as all IT infrastructure and operations. Volker holds Bachelor of Science and Master of Science degrees in Physics from the University of Tübingen.
Gary Palmer MD, MBA oversees all of Actelion’s Medical and Regulatory activities in the United States. Gary has been in the pharmaceutical industry for more than 20 years. He has supported a significant number of products in a number of disease states across therapeutic areas that have included cardiovascular, metabolic disease & diabetes, oncology and neuroscience.
Gary received his MD Degree (MBBCH - Bachelor of Medicine and Bachelor of Surgery) as well as his MBA in South Africa at the University of the Witwatersrand in Johannesburg. Prior to joining the pharmaceutical industry, he practiced medicine in Emergency Care, Gynecology and Family Practice in South Africa.
Bob Smith is responsible for Actelion's sales organization in the United States. He joined Actelion in 2007 as Director of Marketing for the Pulmonary Arterial Hypertension Franchise. He then became Vice President, Western Business Unit before being appointed to his current position in 2012.
Prior to Actelion, Bob was Marketing Director for Nuvelo. He started his career at Bristol-Myers Squibb and has held various sales and marketing roles with increasing responsibility for Centocor and Scios (both Johnson & Johnson operating companies). Bob holds a Bachelor of Business Administration in Marketing from Texas A&M University.
Rahsaan Thompson is Vice President, Law for Actelion US. He is responsible for leading the Actelion Law Department in South San Francisco, California and is in charge of coordinating Law Department support for the Actelion business in the US. Rahsaan joined Actelion in 2011 in the role of Senior Legal Counsel and then served as Associate General Counsel and Secretary before being appointed to his current role.
Before joining Actelion, Rahsaan served as Of Counsel at Quarles & Brady, LLP in Chicago and also held prior in-house roles at Abraxis Bioscience, LLC and McKesson Corporation. He began his law career as an Assistant District Attorney in the Philadelphia District Attorney’s Office. Rahsaan holds a Bachelor of Science degree in Political Science from Southern Methodist University and a J.D. from Hofstra University School of Law.